托珠单抗

Records for this ingredient, by country (identity only).

ATC L04AC · 1 markets · 9 records

托珠单抗 1 markets · 9 records Forms
Filters
MarketCN 9

CN 9 records · 5 shown of 5 Source 国家医保局 医保药品分类与代码数据库 · Data as of 2025-04-04

  • 80 mg/4 mLinjection安维泰托珠单抗施瑞立、雅美罗
  • 80 mg per mL / per unit basis not statedinjection安佰欣托珠单抗考普瑞宁
  • 400 mg/20 mLinjection施瑞立托珠单抗
  • 200 mg/10 mLinjection施瑞立托珠单抗
  • 162 mg/0.9 mLinjectionManufacturer: RocheRegislrationGmbH ×2

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.